DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) is anticipated to post its quarterly earnings results before the market opens on Monday, March 17th. Analysts expect DiaMedica Therapeutics to post earnings of ($0.17) per share for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.
DiaMedica Therapeutics Stock Performance
Shares of DiaMedica Therapeutics stock traded up $0.10 during trading on Friday, hitting $5.77. 34,298 shares of the company's stock were exchanged, compared to its average volume of 69,197. The business has a 50-day simple moving average of $5.95 and a 200-day simple moving average of $5.05. DiaMedica Therapeutics has a 52-week low of $2.14 and a 52-week high of $6.82. The stock has a market capitalization of $246.73 million, a price-to-earnings ratio of -10.30 and a beta of 1.52.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a "buy" rating and set a $7.00 target price on shares of DiaMedica Therapeutics in a report on Friday, November 15th.
Get Our Latest Report on DiaMedica Therapeutics
About DiaMedica Therapeutics
(
Get Free Report)
DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Read More
Before you consider DiaMedica Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DiaMedica Therapeutics wasn't on the list.
While DiaMedica Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
